

X #GonorteGUDebates

SAVE THE DATE



# GO NORTE INTERNATIONAL GU DEBATES

OCTOBER 5<sup>th</sup>-6<sup>th</sup>, 2023

**Venue:**

**Parador de Limpias**

c/ Fuente del Amor 2, Limpias, Cantabria

**Organized by:**



**GONORTE**  
Grupo Oncológico



**THURSDAY, OCTOBER 5<sup>th</sup>**

**09:30-10:00h REGISTRATION**

**10:00h OPENING**

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander  
Dr. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona

**10:15-11:45h PERIOPERATIVE TREATMENT IN GU ONCOLOGY:  
THE DEBATE IS OPEN  
THE CASE OF BLADDER CANCER**

**Chairs:**

Dr. Enrique Grande, Medical Oncology Department, MD Anderson Cancer Center Madrid

Dr. Mario Álvarez Maestro, Urology Department, Hospital Universitario La Paz, Madrid

10:15-10:25h **Questions to audience**

**Perioperative treatment in MIBC: An interactive case**

10:25-10:40h **IO based perioperative treatment in muscle invasive bladder cancer: in favor**

Dr. M<sup>a</sup> José Juan, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

10:40-10:55h **IO based perioperative treatment in muscle invasive bladder cancer: the critical approach**

Dr. Alfonso Gómez de Liaño, Medical Oncology Department, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria

**Voting**

10:55-11:15h **Perioperative treatment in muscle invasive bladder cancer: the expert's vision**

Dr. Michiel Van der Heijden, Medical Oncology Department, Netherlands Cancer Institute, Amsterdam

11:15-11:45h *Discussion*

**11:45-12:15h COFFEE BREAK ☕**

**12:15-13:45h THE CASE OF KIDNEY CANCER**

**Chairs:**

Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

Dr. Felipe Villacampa, Urology Department, Clínica Universidad de Navarra, Madrid

12:15-12:25h **Questions to audience**

**Perioperative treatment in RCC: An interactive case**

12:25-12:40h **IO based perioperative treatment in localized renal cell cancer: in favor**

Dr. Javier Puente, Medical Oncology Department, Hospital Clínico San Carlos, Madrid

12:40-12:55h **IO based perioperative treatment in localized renal cell cancer: the critical approach**

Dr. Guillermo de Velasco, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

**Voting**

12:55-13:15h **IO based perioperative treatment in localized RCC: the expert's vision**

Dr. Jens Bedke, Urology Department, Comprehensive Cancer Center Tübingen-Stuttgart

13:15-13:45h *Discussion*

**13:45-14:30h MEET WITH THE EXPERT SYMPOSIUM**

**Chair:**

Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

**BAVENCIO Meet the expert Prof Grivas: Extend overall survival in UC**

Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center



**14:30-16:00h LUNCH COCKTAIL** 🍷



## 16:00-17:25h **CHALLENGING STANDARDS OF CARE IN BLADDER CANCER TREATMENT**

### **Chairs:**

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

### 16:00-16:15h **The BCG refractory scenario: are the upcoming strategies good enough to replace the standard?**

Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid

### 16:15-16:35h **Are ADCs combinations the new backbone in first line mUC?**

Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center

### 16:35-16:55h **Are the Galsky criteria getting old fashioned in 2023? Are we going to stratify patients in first-line in the near future?**

Dr. Yohann Lorient, Medical Oncology Department, Institut Gustave Roussy, Villejuif, France

### 16:55-17:25h *Discussion*

## 17:25-17:55h **COFFEE BREAK ☕**

## 17:55-19:25h **THINKING OUTSIDE OF THE BOX: OPPORTUNITIES FOR COLLABORATION**

### **Chairs:**

Dr. Laura Basterretxea, Medical Oncology Department, Hospital Universitario Donostia

Dr. Ricardo Fernández, Medical Oncology Department, Instituto Oncológico IMQ Zorrotzaurre, Hospital Universitario de Cruces, Bizkaia

### 17:55-18:10h **Physical exercise and cancer: a possible duet in GU oncology?**

Mr. Mario Redondo, Physiotherapist, Exercise Physiology Cancer Center, Madrid

- 18:10-18:25h **New technologies and prostate cancer patients: is it feasible?**  
Mr. Borja Gómez Mediavilla, Research Nurse, Instituto de Investigación Sanitaria - IDIVAL, Santander
- 18:25-18:40h **Managing elderly GU oncology patients: am I missing something?**  
Dr. Regina Gironés, Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia
- 18:40-18:55h **Oligometastatic disease in GU oncology: facts and “myths”**  
Dr. Alfonso Gómez de Iturriaga, Radiation Oncology Department, Hospital Universitario de Cruces, Bilbao
- 18:55-19:25h *Discussion*

**19:25-20:10h A LOOK INTO THE NEAR FUTURE**

**Chair:**

Dr. Álvaro Pinto, Medical Oncology Department, Hospital Universitario La Paz, Madrid

**Metaverso: ¿el futuro de Internet?**

Mr. Mauro A. Fuentes, Digital Communication Transformation, Communication and Institutional Relations Department, CaixaBank, Madrid

**20:10-20:20h CLOSING OF THE DAY**

**21:00h DINNER ATTENDEES**



**FRIDAY, OCTOBER 6<sup>th</sup>**

**08:30h OPENING**

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Dr. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona

**08:35-09:45h ADVANCED KIDNEY CANCER: FROM THE CLINIC TO THE BASIC SCIENCE**

**Chairs:**

Dr. Jesús García-Donas, Medical Oncology Department, Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

Dr. Teresa Alonso, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid

**08:35-08:55h Certainties and doubts in first-line mRCC**

Dr. Viktor Grünwald, Medical Oncology Department, University Hospital Essen, Germany

**08:55-09:15h Understanding the dynamics of renal cell cancer evolution to improve therapeutics**

Dr. Charlotte Spencer, Research Department of Pathology, Cancer Dynamics Laboratory, Francis Crick Institute, Renal and Skin Unit, The Royal Marsden Hospital, London

**09:15-09:30h Characterizing rare renal cell cancers to guide treatment**

Dr. Cristina Rodríguez-Antona, Established Investigator, Centro Nacional de Investigaciones Oncológicas-CNIO, Madrid

**09:30-09:45h Discussion**

09:45-11:05h **PARPi: THE DEBATE IS OPEN**

**Chairs:**

Dr. Joan Carles, Medical Oncology Department, Hospital  
Universitari Vall d'Hebron, Barcelona

Dr. Mario Domínguez, Urology Department, Hospital Universitario  
Marqués de Valdecilla - IDIVAL, Santander

09:45-10:00h **Questions to audience**

**CPRC and PARP inhibitors: An interactive case**

10:00-10:15h **PARPi: the selection does not matter to me**

Dr. David Lorente, Medical Oncology Department, Hospital  
Provincial de Castellón

10:15-10:30h **PARPi: the selection does matter to me**

Dr. Elena Castro, Medical Oncology Department, Hospital  
Universitario 12 de Octubre, Madrid

**Voting**

10:30-10:50h **PARP inhibition and patient selection: integrating basic  
science and clinical data**

**ONLINE**

Dr. Johann Sebastian de Bono, Medical Oncology Department,  
The Institute of Cancer Research and Royal Marsden, London

10:50-11:05h *Discussion*

11:05-11:35h **COFFEE BREAK** ☕

11:35- 12:20h **MEET WITH THE EXPERT SYMPOSIUM**

**Chair:**

Dr. Ignacio Durán, Medical Oncology Department, Hospital  
Universitario Marqués de Valdecilla - IDIVAL, Santander

**Paradigm shift in the adjuvant treatment of renal cancer from  
a multidisciplinary approach**

Dr. Álvaro Pinto, Medical Oncology Department, Hospital  
Universitario La Paz, Madrid

Dr. Albert Francès, Urology Department, Hospital del Mar - Parc de  
Salut Mar, Barcelona



## 12:20-13:30h **ADVANCED HORMONE-SENSITIVE PROSTATE CANCER**

### **Chairs:**

Dr. Carmen Santander, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza

Dr. Juan Francisco Rodríguez Moreno, Medical Oncology Department, Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

### 12:20-12:35h **A triplet is my standard of care for all mHSPC patients**

Dr. Enrique González-Billalabeitia, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

### 12:35-12:50h **I select very carefully my mHSPC patients for a triplet**

Dr. Miguel Ángel Climent, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

### 12:50-13:10h **Patient selection in mHSPC: Integrating current data**

Dr. Bertrand Tombal, Urology Department, Université Catholique de Louvain, Belgium

### 13:10-13:30h *Discussion*

## 13:30-14:20h **THERAGNOSIS IN PROSTATE CANCER: WHERE ARE WE IN 2023?**

### **Chair:**

Dr. José Luis Pérez Gracia, Medical Oncology Department, Clínica Universidad De Navarra, Pamplona

### 13:30-13:45h **What a clinician should know about PSMA PET in prostate cancer: success and pitfalls**

Dr. Antonio Maldonado, Nuclear Medicine Department, Hospital Universitario Quirónsalud Madrid

### 13:45-14:00h **What can I expect from theragnosis in prostate cancer: the clinician's Perspective**

Dr. Josep M<sup>a</sup> Piulats, Medical Oncology Department, Institut Català d'Oncologia Hospital Duran i Reynals, L'Hospitalet de Llobregat

### 14:00-14:20h *Discussion*

## 14:20-14:25h **CLOSING REMARKS**

## 14:25h **FAREWELL COCKTAIL 🍸**

**NOTES**

A series of horizontal dotted lines for taking notes, spanning the width of the page.



## NOTES

A series of horizontal dotted lines for writing notes, spanning the width of the page.

**NOTES**

A series of horizontal dotted lines for taking notes.



# GO NORTE INTERNATIONAL GU DEBATES

OCTOBER 5<sup>th</sup>-6<sup>th</sup>, 2023

## SPONSORS

### PLATINUM

**MERCK**



### GOLD

**janssen Oncology**

PHARMACEUTICAL COMPANIES OF **Johnson & Johnson**

### SILVER

**Bristol Myers Squibb**



**astellas**



**IPSEN**  
Innovation for patient care

### BRONZE



**AstraZeneca**



**RECORDATI  
RARE DISEASES**



**Pfizer**

**GILEAD**  
Oncology

## UNDER THE AUSPICE OF

**SEOM**  
Sociedad Española  
de Oncología Médica

SEOM es una marca registrada.  
El uso de SEOM no implica la  
organización ni el patrocinio del evento.



**aseica**

Solicitada la acreditación al Sistema Acreditador de Formación Continua de las Profesiones Sanitarias de la Comunidad de Madrid. La asistencia del 100% al evento presencial es obligatoria para obtener la acreditación. No recibirán los créditos del Sistema acreditador ni estudiantes, ni médicos internos residentes, ya que están excluidos del mismo.

SECRETARÍA TÉCNICA:

**tactics**